BioInvent International
25.3 SEK +0.6%1 investor is following this company
BioInvent International is active in the pharmaceutical industry. The company focuses on the research and development of antibody drugs used in the treatment of cancer. The company has its own development platform and collaborations take place via the company's partners. In the early development phase, the company is working to recreate the disease biology to get indications about the substance's effect on the disease. The head office is located in Lund, Sweden.
Revenue
71.46M
EBIT %
-517.69 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
BINV
Daily low / high price
24.75 / 25.85
SEK
Market cap
1.66B SEK
Turnover
1.54M SEK
Volume
61K
Latest videos
Financial calendar
General meeting
2024-05-03
Interim report
2024-08-29
Interim report
2024-10-31
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Redmile Group, LLC | 15.4 % | 15.4 % |
Van Herk Investments | 10.1 % | 10.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
BioInvent International AB: BioStock: BioInvent selected to present at ASCO in Chicago
Redeye: BioInvent Q1 2024 - Approaching Catalysts
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools